NCT06208761CompletedPhase 2
Triphala Supplementation and High-intensity Interval Exercise and Immune System Function and Oxidative Stress
Effects of Triphala Supplementation and High-intensity Interval Exercise on Immune System Function and Oxidative Stress in People With Long COVID
Source: ClinicalTrials.gov · Last updated 17 Jan 2024
Brief summary (registry, in English)
One hundred and forty-one male and female participants aged 18-59 years were randomly divided into 4 groups: 1) control group: neither received exercise program nor supplement but received placebo capsule for 8 weeks 2) experiment-1: received Triphala capsule at 1,000 mg/day, before breakfast for 500 mg and before dinner for 500 mg, for consecutive 5 days/week for 8 weeks 3) experiment-2: received leg cycling exercise program in the form of high-intensity interval training (HIIT) for 28 min/day, 3 days/week for 8 weeks and 4) experiment-3: received both Triphala capsule and HIIT in the similar extent to the experiment-1 and experiment-2 groups for 8 weeks. Immune system function and oxidative stress including blood interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), malondialdehyde (MDA), and protein carbonyls levels were analyzed. In addition, blood alanine aminotransferase (ALT) enzyme and creatinine levels were also analyzed for determining liver and kidney toxicity, particularly in the Triphala supplementation and combined Triphala supplementation and HIIT groups.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 141 (actual)
- First submitted
- 21 Dec 2023
- Start date
- 9 May 2023
- Primary completion date
- 22 Oct 2023
- Lead sponsor
- Burapha University
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06208761
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 141
- From 9 May 2023 to the primary completion date, 22 Oct 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Food allergy, especially herbs i.e., emblic myrobalan, chebulic myrobalan, beleric myrobalan
- Hypertension, diabetes, cardiovascular disease, respiratory disease, endocrine disease, neuromuscular disease, musculoskeletal disease, liver disease, renal disease, immune disease, infectious disease, or cancer
- Current signs or symptoms of infection, i.e., fever, hyperpnea, dyspnea, and palpitations
Other
- Regular exerciser (\>2 times per week or \>150 min per week)
- Regular intake of dietary supplements, i.e., vitamins, antioxidants, herbs
- Regular smokers or alcohol drinkers (\>2 times per week)
Who the study is looking for
- Passed COVID-19 infection for at least 4 weeks with a symptom of long COVID including regular fatigue, headache, inability to concentrate, hair loss, and dyspnea (the symptom was exacerbated by exercise or concentration)
- Aged between 18 to 59 years
- Normal body mass index (BMI 18.5 to 24.9 kg/m2)
Age in the registry: 18 years to 59 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Allied Health Sciences, Burapha University Coordinator of this site? Confirm its status | Mueang | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.